Table 1 Open in new tab Patient and...

Variables

Systematic LND
n = 150

Lobe-specific LND
n = 209

P value

Clinical variables

Age, years

66 (60–72)

70 (64–76)

<0.0001

Sex, male/female

111 (74.0%)/39 (26.0%)

146 (69.9%)/63 (30.1%)

0.41

Whole tumor size, cm

3.1 (2.4–4.3)

3.1 (2.3–4.0)

0.45

Solid component size, cm

3.0 (2.3–4.1)

2.8 (2.2–3.8)

0.17

C/T ratio

1.0 (1.0–1.0)

0.24

SUVmax

10.3 (6.2–15.4)

8.8 (4.7–13.9)

0.042

cT, T1/T2/T3/T4

67(44.7%)/54(36.0%)/21(14.0%)/8(5.3%)

106(50.7%)/71(34.0%)/22(10.5%)/10(4.8%)

0.64

cN, N0/N1/N2

64 (42.7%)/57 (38.0%)/29 (19.3%)

124 (59.3%)/65 (31.1%)/20(9.6%)

0.0025

Side, right/left

91 (60.7%)/59 (39.3%)

107 (51.2%)/102 (48.8%)

0.085

Lobe, upper/lower

86 (57.3%)/64 (42.7%)

114 (54.5%)/95 (45.5%)

0.67

Pathological and Postoperative variables

Histology
Adenocarcinoma
Squamous cell carcinoma
Others

100 (66.7%)
31 (20.7%)
19 (12.6%)

127 (60.8%)
49 (23.4%)
33 (15.8%)

0.50

Pathologic tumor size, cm

3.0 (2.5–4.2)

3.0 (2.3–4.0)

0.34

Pathologic invasive size, cm

3.0 (2.1–4.0)

2.6 (1.9–3.5)

0.11

Lymphatic invasion

107 (71.3%)

118 (56.5%)

0.0041

Vascular invasion

121 (80.7%)

158 (75.6%)

0.30

Pleural invasion

71 (47.3%)

85 (40.7%)

0.24

Number of dissected LNs

21 (16–29)

17 (13–25)

<0.0001

Median number of dissected metastasis LNs

3 (2–6)

2 (1–4)

<0.0001

Pathologic N status
N1
N2

76 (50.7%)
74 (49.3%)

139 (66.5%)
70 (33.5%)

0.0032

Detail of N2 status
^aN2 in lobe-specific LND field
^bN2 in systematic LND field

^c67 (44.7%)
^c25 (16.7%)

70 (33.5%)
0 (0%)

0.037
<0.0001

Adjuvant chemotherapy

76 (50.7%)

101 (48.3%)

0.67

Recurrence

77 (51.3%)

96 (45.9%)

0.34

Recurrence pattern
Locoregional
Distant
Locoregional and Distant

16 (20.8%)
37 (48.1%)
24 (31.1%)

35 (36.5%)
38 (39.6%)
23 (23.9%)

0.079

Lymph node relapse

24 (16.0%)

41 (19.6%)

0.41

Table 1

Open in new tab

Patient and tumor characteristics of the systematic and lobe-specific LND groups in all cohort

Variables		Systematic LND n = 150	Lobe-specific LND n = 209	P value
Clinical variables	Age, years	66 (60–72)	70 (64–76)	<0.0001
	Sex, male/female	111 (74.0%)/39 (26.0%)	146 (69.9%)/63 (30.1%)	0.41
	Whole tumor size, cm	3.1 (2.4–4.3)	3.1 (2.3–4.0)	0.45
	Solid component size, cm	3.0 (2.3–4.1)	2.8 (2.2–3.8)	0.17
	C/T ratio	1.0 (1.0–1.0)	1.0 (1.0–1.0)	0.24
	SUVmax	10.3 (6.2–15.4)	8.8 (4.7–13.9)	0.042
	cT, T1/T2/T3/T4	67(44.7%)/54(36.0%)/21(14.0%)/8(5.3%)	106(50.7%)/71(34.0%)/22(10.5%)/10(4.8%)	0.64
	cN, N0/N1/N2	64 (42.7%)/57 (38.0%)/29 (19.3%)	124 (59.3%)/65 (31.1%)/20(9.6%)	0.0025
	Side, right/left	91 (60.7%)/59 (39.3%)	107 (51.2%)/102 (48.8%)	0.085
	Lobe, upper/lower	86 (57.3%)/64 (42.7%)	114 (54.5%)/95 (45.5%)	0.67
Pathological and Postoperative variables	Histology Adenocarcinoma Squamous cell carcinoma Others	100 (66.7%) 31 (20.7%) 19 (12.6%)	127 (60.8%) 49 (23.4%) 33 (15.8%)	0.50
	Pathologic tumor size, cm	3.0 (2.5–4.2)	3.0 (2.3–4.0)	0.34
	Pathologic invasive size, cm	3.0 (2.1–4.0)	2.6 (1.9–3.5)	0.11
	Lymphatic invasion	107 (71.3%)	118 (56.5%)	0.0041
	Vascular invasion	121 (80.7%)	158 (75.6%)	0.30
	Pleural invasion	71 (47.3%)	85 (40.7%)	0.24
	Number of dissected LNs	21 (16–29)	17 (13–25)	<0.0001
	Median number of dissected metastasis LNs	3 (2–6)	2 (1–4)	<0.0001
	Pathologic N status N1 N2	76 (50.7%) 74 (49.3%)	139 (66.5%) 70 (33.5%)	0.0032
	Detail of N2 status ^aN2 in lobe-specific LND field ^bN2 in systematic LND field	^c67 (44.7%) ^c25 (16.7%)	70 (33.5%) 0 (0%)	0.037 <0.0001
	Adjuvant chemotherapy	76 (50.7%)	101 (48.3%)	0.67
	Recurrence	77 (51.3%)	96 (45.9%)	0.34
	Recurrence pattern Locoregional Distant Locoregional and Distant	16 (20.8%) 37 (48.1%) 24 (31.1%)	35 (36.5%) 38 (39.6%) 23 (23.9%)	0.079
	Lymph node relapse	24 (16.0%)	41 (19.6%)	0.41

Variables		Systematic LND n = 150	Lobe-specific LND n = 209	P value
Clinical variables	Age, years	66 (60–72)	70 (64–76)	<0.0001
	Sex, male/female	111 (74.0%)/39 (26.0%)	146 (69.9%)/63 (30.1%)	0.41
	Whole tumor size, cm	3.1 (2.4–4.3)	3.1 (2.3–4.0)	0.45
	Solid component size, cm	3.0 (2.3–4.1)	2.8 (2.2–3.8)	0.17
	C/T ratio	1.0 (1.0–1.0)	1.0 (1.0–1.0)	0.24
	SUVmax	10.3 (6.2–15.4)	8.8 (4.7–13.9)	0.042
	cT, T1/T2/T3/T4	67(44.7%)/54(36.0%)/21(14.0%)/8(5.3%)	106(50.7%)/71(34.0%)/22(10.5%)/10(4.8%)	0.64
	cN, N0/N1/N2	64 (42.7%)/57 (38.0%)/29 (19.3%)	124 (59.3%)/65 (31.1%)/20(9.6%)	0.0025
	Side, right/left	91 (60.7%)/59 (39.3%)	107 (51.2%)/102 (48.8%)	0.085
	Lobe, upper/lower	86 (57.3%)/64 (42.7%)	114 (54.5%)/95 (45.5%)	0.67
Pathological and Postoperative variables	Histology Adenocarcinoma Squamous cell carcinoma Others	100 (66.7%) 31 (20.7%) 19 (12.6%)	127 (60.8%) 49 (23.4%) 33 (15.8%)	0.50
	Pathologic tumor size, cm	3.0 (2.5–4.2)	3.0 (2.3–4.0)	0.34
	Pathologic invasive size, cm	3.0 (2.1–4.0)	2.6 (1.9–3.5)	0.11
	Lymphatic invasion	107 (71.3%)	118 (56.5%)	0.0041
	Vascular invasion	121 (80.7%)	158 (75.6%)	0.30
	Pleural invasion	71 (47.3%)	85 (40.7%)	0.24
	Number of dissected LNs	21 (16–29)	17 (13–25)	<0.0001
	Median number of dissected metastasis LNs	3 (2–6)	2 (1–4)	<0.0001
	Pathologic N status N1 N2	76 (50.7%) 74 (49.3%)	139 (66.5%) 70 (33.5%)	0.0032
	Detail of N2 status ^aN2 in lobe-specific LND field ^bN2 in systematic LND field	^c67 (44.7%) ^c25 (16.7%)	70 (33.5%) 0 (0%)	0.037 <0.0001
	Adjuvant chemotherapy	76 (50.7%)	101 (48.3%)	0.67
	Recurrence	77 (51.3%)	96 (45.9%)	0.34
	Recurrence pattern Locoregional Distant Locoregional and Distant	16 (20.8%) 37 (48.1%) 24 (31.1%)	35 (36.5%) 38 (39.6%) 23 (23.9%)	0.079
	Lymph node relapse	24 (16.0%)	41 (19.6%)	0.41

Values are median (interquartile range) or n (%). LND, lymph node dissection; C/T ratio, consolidation tumor ratio; SUV, standard uptake value; LNs, lymph nodes.

^aN2 in lobe-specific LND field is defined as N2 lymph node that could be dissected by lobe-specific LND

^bN2 in systematic LND field is defined as N2 lymph node that could not be dissected by lobe-specific LND but could be dissected by systematic LND

^c18 patients had both N2 lymph node in lobe-specific LND and systematic LND fields

This Feature Is Available To Subscribers Only